Lasa Supergenerics Board Approves 11th AGM, Director Re-appointment, and More
Lasa Supergenerics Limited's Board approved the 11th AGM on September 30, 2026. Key decisions include re-appointing Director Omkar Herlekar and appointing Janardan Savala as Executive Director for five years from August 26, 2026. The company will also seek shareholder approval for donations up to ₹2 crore annually and managerial remuneration up to ₹3 crore annually.
The outcomes of the board meeting, including the AGM schedule, director re-appointments, and approvals for donations and remuneration, are important for corporate governance and operational continuity. The enhanced borrowing powers could also facilitate future growth, though the direct financial impact is not immediate.
The announcement details routine corporate actions such as board meeting outcomes, AGM schedule, director re-appointments, and approvals for managerial remuneration and donations. These are standard procedural matters and do not indicate a significant positive or negative shift in the company's performance or outlook.
Lasa Supergenerics Limited announced the outcome of its Board Meeting held on September 09, 2026. The Board approved the Notice of the Eleventh (11th) Annual General Meeting (AGM), scheduled for Wednesday, September 30, 2026, at 9:30 AM via Video Conferencing (VC)/Other Audio-Visual Means (OAVM). The Directors' Report for the financial year ended March 31, 2026, along with reports on Corporate Governance and Management Discussion and Analysis, was also approved.
The Board appointed Shravan A. Gupta & Associates as the scrutinizer for the 11th AGM. Additionally, Mr. Omkar Herlekar was re-appointed as a Director, liable to retire by rotation. The Register of Members and Share Transfer Books will be closed from Wednesday, September 23, 2026, to Tuesday, September 29, 2026, inclusive.
Further, the company's notice for the 11th AGM detailed several key resolutions. These include the adoption of Audited Financial Statements for the financial year ended March 31, 2026, and the re-appointment of Mr. Omkar Herlekar. Special businesses include the appointment of Ms. Shivam Sharma & Associates as secretarial auditor for a five-year term from FY2025-26 to FY2029-30, and the appointment of Mr. Janardan Savala as Whole-Time Director, designated as Executive Director, for a five-year term commencing August 26, 2026. The AGM notice also covers resolutions for donation approvals up to ₹2 crore per annum to charitable trusts, including Dr. Omkar Herlekar Foundation, and the approval for total managerial remuneration up to ₹3 crore per annum in case of inadequate or no profits. Furthermore, the Board sought approval for enhanced borrowing powers under Section 180(1)(c) of the Companies Act, 2013.
What to do with a filing like this
Lasa Supergenerics Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lasa Supergenerics Limited. Read the original for the full detail.